Shareholders Approve Capital Band Increase, Enabling Future Financing for Distressed Addex Therapeutics
ADXN sits 16% above its 52-week low of $5.41.
Summary
Addex Therapeutics shareholders approved an increase to the company's capital band and conditional share capital, a critical step for the financially distressed company to raise future capital.
Key Events · Financing and Capital Events · ADXN
-
Shareholder Approval of Capital Increase
Shareholders approved amendments to the Articles of Association to increase the capital band and conditional share capital, enabling the company to issue more shares for future financing. This follows the AGM agenda announced on June 5, 2026.
-
Board and Management Re-elected
All current board members, including Chairman Dr. Vincent Lawton and CEO Tim Dyer, were re-elected, along with the auditors and independent voting rights representative.
-
Financial Statements Approved
The annual report, consolidated financial statements, and annual financial statements for 2025 were approved, along with compensation reports and discharge for management.
Analysis · ADXN · Life Sciences
This approval allows Addex Therapeutics to issue more shares and raise capital, which is essential given its recent disclosures of a critically low cash position and substantial doubt about its ability to continue as a going concern. While enabling future financing, this also signals potential significant dilution for existing shareholders.
At the time of this filing, ADXN was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.